Compare PIII & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | LSTA |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 28.9M |
| IPO Year | 2021 | 2000 |
| Metric | PIII | LSTA |
|---|---|---|
| Price | $7.60 | $1.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $9.00 | ★ $15.00 |
| AVG Volume (30 Days) | 18.7K | ★ 359.0K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,459,080,000.00 | $35,283,868.00 |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $1.52 | $0.99 |
| 52 Week High | $16.89 | $5.07 |
| Indicator | PIII | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 35.32 | 47.50 |
| Support Level | $2.39 | $1.11 |
| Resistance Level | $11.55 | $2.08 |
| Average True Range (ATR) | 0.45 | 0.27 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 15.67 | 25.34 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.